Protalix BioTherapeutics, Inc. Earnings Recaps
Q3 2025
Nov 13, 2025
Protalix BioTherapeutics reported strong year-to-date revenue growth of 24%, though third-quarter revenues showed a slight decline of 1% compared to the previous year, reflecting ongoing inventory management by key partners.
Key takeaways
- Total revenues for the first nine months of 2025 reached $46.4 million, marking a 24% year-over-year increase.
- Third-quarter revenue was $17.9 million, down 1% year-over-year due to variable inventory control by partners.
- The company is advancing its PRX-115 candidate for the treatment of uncontrolled gout, having filed for a Phase 2 clinical trial.
- Research and development expenses surged by 58% for the first nine months, emphasizing continued investment in pipeline projects.
- Protalix maintains a strong cash position and positive net income, supporting its strategic focus on commercial success and innovation.
Q2 2025
Aug 14, 2025
Protalix BioTherapeutics reported a robust 50% year-over-year increase in Q2 2025 revenues, driven by strong sales of its Fabry disease treatment, Elfabrio, through its partner Chiesi.
Key takeaways
- Revenues from selling goods reached $15.4 million, reflecting a 16% increase from Q2 2024, primarily due to Elfabrio sales.
- Protalix anticipates Elfabrio royalties will exceed $100 million by 2030, targeting a 15%-20% market share in the $3.2 billion Fabry market.
- The company is progressing toward a Phase II study for its gout treatment candidate, PRX-115, expected to commence in late 2025.
- Chiesi's ongoing investments and focus on Elfabrio position Protalix favorably for future growth in the rare disease sector.
- Eyal Rubin is stepping down as CFO, succeeded by Gilad Mamlok, marking a transition in financial leadership as the company aims for continued advancement.